In agreement with this finding, in APP transgenic mice and in the postmortem frontal cortex of AD patients, it has been shown that the impairment of SOD activity occurs concomitantly with the increase in Aβ levels [45, 51]. This evidence concerns the gene APP and Alzheimer disease.